Patients with chronic hepatitis B (CHB) can be successfully treated using nucleos (t) ide
analogs (NA), but drug-resistant hepatitis B virus (HBV) mutants frequently arise, leading to …

Diseases (AASLD) also presented and continued to revise their clinical practice guidelines,
and the latest updates were in 2015, 2017, and 2018. However, since the medical …

Background The novel prodrug tenofovir alafenamide delivers the nucleotide reverse
transcriptase inhibitor tenofovir to target cells more efficiently at a lower dose than tenofovir …

Background & Aims Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to
treat patients with chronic hepatitis B virus (HBV) infection at a lower dose than tenofovir …

Background Tenofovir alafenamide is a novel prodrug formulated to deliver the active
metabolite to target cells more efficiently than tenofovir disoproxil fumarate at a lower dose …

临床上广泛使用的一线抗HBV 药物核苷(酸) 类似物(NAs) 可有效地抑制HBV DNA 复制,
显著减缓慢性乙型肝炎(CHB) 患者的疾病进展, 减少包括肝衰竭和肝癌在内的终末期肝病的发生 …

Background Tenofovir disoproxil fumarate (DF) is a nucleotide analogue and a potent
inhibitor of human immunodeficiency virus type 1 reverse transcriptase and hepatitis B virus …

BACKGROUND & AIMS: Tenofovir disoproxil fumarate (TDF), a nucleotide analogue and
potent inhibitor of hepatitis B virus (HBV) polymerase, showed superior efficacy to adefovir …

In the setting of intensive immunosuppression for the management of rejection in solid organ
transplant (SOT) recipients, or graft-versus-host disease (GVHD) in hematopoietic stem cell …

Aims The Korean Association for the Study of the Liver (KASL) Practice Guidelines for
Management of Hepatitis C were first established in 2004, and revised in 2013, when direct …